MISSISSAUGA, Ontario, June 29, 2011 /PRNewswire/ -- CardioGenics Holdings Inc. (CGNH.OB) announced today that the United States Patent & Trademark Office (USPTO) has notified the company that its patent application has been granted (issued patent # 7,964,415). This patent covers CardioGenics Inc.'s proprietary signal amplification technology, which is a key component of the core technology for CardioGenics' Ultra-Sensitive QL Care™ Analyzer. CardioGenics' unique methodology for signal amplification enables a decrease in the amount of binding reagents used in immunoassay diagnostic tests, such as those to be performed on the QL Care™ Analyzer, which, in turn, results in improved signal-to-noise ratio thereby increasing testing sensitivity.
"We are very pleased that the USPTO has recognized the unique nature of CardioGenics' signal amplification technology," said Dr. Yahia Gawad, CEO of CardioGenics. "This patent is an important addition to our patent portfolio since it addresses a key component of the technology that permits the ultra-sensitive performance of our QL Care™ Analyzer," continued Dr. Gawad.
About CardioGenics Holdings Inc.
Through its operating subsidiaries, the Company develops ultra-sensitive analyzers and other products targeting the immunoassay segment of the Point-Of-Care IVD testing market. It has developed the QL Care™ Analyzer, a proprietary and ultra-sensitive Point-Of-Care immuno-analyzer, which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, the Company has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. The Company's proprietary microspheres technology and SAVAsphere™ magnetic beads are developed